Related content

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

By              

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1199-1203

Spandidos Publications

Access to resources Recommend Favorite

Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics

By            

International Journal of Oncology, Vol. 43, Iss. 3, 2013-01 ,pp. : 895-902

Spandidos Publications

Access to resources Recommend Favorite

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

By O’Connor R.   O’Leary M.   Ballot J.   Collins C.   Kinsella P.   Mager D.   Arnold R.   O’Driscoll L.   Larkin A.   Kennedy S.   Fennelly D.   Clynes M.   Crown J.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 79-87

Springer Publishing Company

Access to resources Recommend Favorite

Deleted in liver cancer1 inhibits cell growth and tumorigenicity in human pancreatic cancer

By          

Oncology Letters, Vol. 6, Iss. 2, 2013-01 ,pp. : 521-524

Spandidos Publications

Access to resources Recommend Favorite

Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells

By Wen Chuangyu   Huang Lanlan   Chen Junxiong   Lin Mengmeng   Li Wen   Lu Biyan   Rutnam Zina Jeyapalan   Iwamoto Aikichi   Wang Zhongyang   Yang Xiangling   Liu Huanliang  

International Journal of Oncology, Vol. 47, Iss. 5, 2015-11 ,pp. : 1663-1671

Spandidos Publications

Access to resources Recommend Favorite